GREAT PERSPECTIVE: As I see it, if Anavex licenses IP to established BP’s or enters a JV (joint venture) with established BP’s THOSE entities will be setting the price.
Never thought about it that way, but it makes sense, and avoids a big issue. Makes licensing for different diseases a snap, and enables us to charge based on need.